摘要
活血化瘀中成药多源于中医经方验方,抗血栓疗效及安全性有据可循,但其配伍规律及作用机制尚不明确。本文结合中医传承辅助系统(V2.0)、IPA(ingenuity pathway analysis)等生物信息学方法,分析活血化瘀中成药的配伍规律和抗血栓作用机制。基于中医传承辅助系统分析活血化瘀中成药配伍规律,得到配伍最常用的3味中药:丹参(Salvia miltiorrhiza Bge.)、川芎(Ligusticum chuanxiong Hort.)和红花(Carthamustinctorius L.)。基于IPA分析上述3味活血化瘀中药活性成分抗血栓作用机制,得到25个单体和29个血栓相关分子的作用网络关系。29个分子中有23个分子与炎症反应有关,关系最密切的炎症分子为NOS2、PTGS2、IL-6、TNF和IL-1β。由此推测,含丹参、川芎和红花活血化瘀中成药抗血栓作用,主要与其抑制炎症反应有关。抑制炎症反应,尤其是抑制炎症相关分子NOS2、PTGS2、IL-6、TNF、IL-1β及相关通路,将成为阐明含丹参、川芎和红花活血化瘀中成药抗血栓作用一个新的切入点。
Chinese traditional patent medicine for promoting blood circulation and removing blood stasis（PBCRBS） originated from traditional Chinese medicine theory and had approved efficacy and safety standards. However, its compatibility regularity and anti-thrombotic mechanism is not clear. To analyze the compatibility regularity and anti-thrombotic mechanism of Chinese traditional patent medicine for PBCRBS, a statistical and bioinformatics analysis was carried out using traditional Chinese medicine inheritance support system（TICMISS, V2.0） and ingenuity pathway analysis（IPA）. The compatibility regularity analysis shows that the most commonly used herb combinations are Danshen（Salvia miltiorrhiza Bge.）, Chuanxiong（Ligusticum chuanxiong Hort.） and Honghua（Carthamustinctorius L.）. The anti-thrombotic mechanism analysis reveals that 25 ingredients have an effect on 29 thrombosis related molecules which 23 molecules are related to inflammation response. Furthermore, there are 5 inflammation molecules（NOS2, PTGS2, IL6, TNF, IL1β） served as major targets. At the same time, Danshen, Chuangxiong and Honghua mainly used as sovereign herb or minister herb in the application of cardiovascular and cerebrovascular diseases. Therefore, Chinese traditional patent medicine for PBCRBS probably has an effect on anti-thrombotic activity through inhibiting the inflammatory response. In summary, the most commonly used herb combinations of Chinese traditional patent medicine for PBCRBS are Danshen, Chuanxiong and Honghua. Inhibiting inflammatory response, especially inflammation related molecules（NOS2, PTGS2, IL6, TNF and IL1β）, is probably a new starting point to clarify the anti-thrombotic mechanism of Chinese patent medicine for PBCRBS.
出处
《药学学报》
CAS
CSCD
北大核心
2015年第9期1135-1141,共7页
Acta Pharmaceutica Sinica
基金
国家重点基础研究发展计划("973"计划)资助项目(2014CB542902)
国家自然科学基金资助项目(81274128
81303144)
天津市高等学校创新团队(TD2-5031)
关键词
活血化瘀
中成药
配伍规律
抗血栓
抗炎
promoting blood circulation and removing blood stasis
Chinese traditional patent medicine
compatibility regularity
anti-thrombotic
anti-inflammation
